Flores-Ortega A, Rivera-López E, Guillén-González MA, Vergara-López A

Language: Spanish
References: 22
Page: 11-17
PDF size: 199.37 Kb.

ABSTRACT

Background: A timely diagnosis and the availability of an adequate management paradigm, along with a relatively benign biological behavior, make of well differentiated thyroid cancer (WTC) a neoplasm with a good prognosis. The present report describes the experience with this tumor at our Institution. Material and methods: It is a descriptive, cross-sectional and observational study. We reviewed the medical records of patients with the diagnosis of thyroid cancer between January 2000 and December 2008. The following variables were analyzed: gender, age at diagnosis, presenting complaint, time between onset of symptom and diagnosis, histopathological diagnosis, TNM stage, treatment, recurrences, thyroglobulin level, and activity/death at the time of the study. Results: 263 medical records of patients with WTC were reviewed; there was a female predominance with a ratio of 11:1; the average age at diagnosis was 42 years, the time between the initial complaint and diagnosis was, on average 1 year. Papillary cancer was present in 90.1% of patients and follicular in 9.9%. Ninety seven patients (35%) showed recurrence. Recurrence was associated with age at diagnosis from 20 to 29 years, an inappropriate initial surgical approach and an inadequate ablative therapy. Conclusions: Our results are comparable with those of other studies. Coincidences were found in age at diagnosis, histology, and ablative therapy. In our center, we apply the American Thyroid Association Guidelines.

REFERENCES

1. Mohar A, Frías-Mendevil M, Suchil-Bernal L, Mora-Macías T, de la Garza J. Epidemiología descriptiva de cáncer en el Instituto Nacional de Cancerología de México. Salud Publica Mex 1997; 39: 253-258.

2. Registro Histopatológico de Neoplasias Malignas en México 2001. Disponible en: http://www.dgepi.salud.gob.mx/diveent/rhnm-01/rhnm-01.htm.

3. The American Thyroid Association Guidelines Taskforce. Management guidelines for patients with thyroid nodules and differentiated thyroid cancer. Thyroid 2006; 16: 1-34.

4. American Joint Committee on Cancer. Comparison Guide: Cancer staging manual, fifth versus sixth edition. Disponible en: http://www.cancer staging.org

5. Schlumberger MJ. Papillary and follicular thyroid carcinoma. N Engl J Med 1998; 338: 297-306.

6. Sherman SI. Thyroid carcinoma. Lancet 2003; 361: 501-511.

7. Hay ID, Thompson GB, Grant CS, Bergstralh EJ, Dvorak CE, Gorman CA et al. Papillary thyroid carcinoma managed at the Mayo Clinic during six decades (1940-1999): temporal trends in initial therapy and long-term outcome in 2,444 consecutively treated patients. World J Surg 2002; 26: 870-885.

8. Mazzaferri EL, Kloos RT. Current approaches to primary therapy for papillary and follicular thyroid cancer. J Clin Endocrinol Metab 2001; 80: 1447-1463.

9. Schlumberger MJ. Papillary and follicular thyroid carcinoma. Bailliere´s Clin Endocrinol Metab 2000; 14: 601-613.

10. Rivera-Moscoso R, Hernández-Jiménez S, Ochoa-Sosa CA, Rodríguez-Carranza SI, Torres-Ambriz P. Diagnóstico y tratamiento del nódulo tiroideo. Posición de la Sociedad Mexicana de Nutrición y Endocrinología. Disponible en: htpp//www.endocrinologia.org.mx/v2/paginas/concenso.php

11. Pacini F, Schlumberger M, Drulle H, Elisei R, Smit JWA, Wiersinga W, European Thyroid Cancer Taskforce. European consensus for the management of patients with differentiated thyroid carcinoma of the follicular epithelium. Euro J Endocrinol 2006; 154: 787-803.

12. Grupo de Consenso en Tiroides. Guía Clínica para el diagnóstico y tratamiento del cáncer diferenciado de tiroides. Sociedad Mexicana de Nutrición y Endocrinología. Disponible en: htpp//www.endocrinologia.org.mx/v2/paginas/concenso.php

13. Van den Bruel A, Moreno-Reyes R, Daumerie C, Glinoer D. Is the management of thyroid nodules and differentiated thyroid cáncer in accordance with recent consensus guidelines? Results of a national survey. Clin Endocrinol 2008; 68: 599-604.

14. Suhail AR, Woodhouse JY. Ablation of the thyroid remnant and 131I dose in differentiated thyroid cancer. Clin Endocrinol 2000; 52: 765-773.

15. Mäenpää HO, Heikkonen J, Vaalavira L, Tenhunem M, Joensuu H. Low vs high radioiodine activity to ablate the thyroid after thyroidectomy for cancer: a randomized study. PLoS ONE 2008; 3(4):e 1885. Disponible en: htpp//www.plosone.org/article/info%3Adoi%2F10.1371%2Fjournal.pone.0001885.

16. Ringel MD, Ladenson PW. Controversies in the follow-up and management of well-differentiated thyroid cancer. Endocr Relat Cancer 2004; 11: 97-116.

17. Sawka AM, Thephamongkhoi K, Brouwers M, Thabane L, Browman G, Gerstein HC. A systematic review and metaanalysis of the effectiveness or radioactive iodine remnant ablation for well-differentiated thyroid cancer. J Clin Endocrinol Metab 2004; 89: 3668-3676.

18. Van Nostrand D. The benefits and risks of 131I therapy in patients with well-differentiated thyroid cancer. Thyroid 2009; 19: 1381-1391.

19. Cooper DS, Specker B, Ho M, Sperling M, Ladenson PW, Ross DS, Ain KB, Bigos ST, Brierley JD, Haugen BR, Klein I. Robbins J, Sherman SI, Taylor T, Maxon HR. Thyrotropin suppression and disease progression in patients with differentiated thyroid cancer: results from the National Thyroid Cancer Treatment Cooperative Registry. Thyroid 1998; 8: 737-744.

20. Pujol P, Daures JP, Nsakala N, Baldet L, Bringer J, Jaffiol C. Degree or thyrotropin suppression as a prognostic determinant in differentiated thyroid cancer. J Clin Endocrinol Metab 1996; 81: 4318-4323.

21. Hovens GC, Stokkel MP, Kievit J, Corssmit EP, Pereira AM, Romijn JA, Smit JW. Associations of serum thyrotropin concentrations with recurrence and death in differentiated thyroid cancer. J Clin Endocrinol Metab 2007; 92: 2610-2615.

22. The American Thyroid Association (ATA) Guidelines Taskforce on Thyroid Nodules and Differentiated Thyroid Cancer. Revised American Thyroid Association management guidelines for patients with thyroid nodules and differentiated thyroid cancer. Thyroid 2009; 19: 1167-1214.